

## Company Presentation

### Australian Non-deal roadshow and Bell Potter Healthcare Conference

**PERTH, Australia, 9 March 2026:** Artrya Limited (ASX: AYA) (**Artrya** or the **Company**), a medical technology company commercialising its Salix® AI-powered cloud platform, for the near real time, point of care assessment and management of coronary artery disease, is pleased to announce that Co-Founder and Chief Executive Officer, John Konstantopoulos, and Executive Chair, Bernie Ridgeway, will be conducting a non-deal roadshow this week, meeting with existing and prospective investors and research analysts in Sydney and Melbourne.

The Company's Presentation for this roadshow is attached.

Additionally, Co-Founder and Chief Executive Officer, John Konstantopoulos, will attend the Bell Potter Healthcare Conference in Sorrento, Victoria on 12 March 2026, where he will participate in an analyst interview and meet with investors.

The Bell Potter Healthcare Conference brings together companies and investors to showcase leading small and mid-cap healthcare companies from across Australasia.

- Ends -

This ASX Announcement is authorised for release by the Board of Artrya Limited.

#### About Artrya

Artrya Limited (ASX:AYA) is an Australian medical technology company developing AI-powered solutions to improve the detection and management of coronary artery disease. Its proprietary software analyses coronary CT scans to identify key biomarkers of heart disease, supporting clinicians in diagnosing patients more accurately and efficiently. Artrya's mission is to advance cardiac care through innovative technology, with regulatory and commercial activities underway across key international markets.

For more information visit [www.artrya.com](http://www.artrya.com) or follow us on LinkedIn at [www.linkedin.com/company/artrya](http://www.linkedin.com/company/artrya)

#### Forward Looking Statements

This Announcement may contain forward-looking statements, including estimates, projections and other forward-looking information (**Estimates** and **Projections**). Forward-looking statements can generally be identified by the use of forward-looking words such as “expect”, “anticipate”, “likely”, “intend”, “should”, “could”, “may”, “predict”, “plan”, “propose”, “will”, “believe”, “forecast”, “estimate”, “target”, “outlook”, “guidance” and other similar expressions within the meaning of securities laws of applicable jurisdictions and include, but are not limited to, indications of, or guidance or outlook on, future earnings or financial position or performance of Artrya. The Estimates and Projections are based on information available to Artrya as at the date of the Announcement, are based upon management's current expectations, estimates, projections, assumptions and beliefs in regards to future events in respect to Artrya's business and the industry in which it operates which may in time prove to be false, inaccurate or incorrect. The Estimates and Projections are provided as a general guide and should not be relied upon as an indication or guarantee of future performance. The bases for these statements are subject to risk and uncertainties that might be out of control of Artrya and may cause actual results to differ from the Announcement. No representation, warranty, or guarantee, whether express or implied, is made or given by Artrya in relation to any Estimates and Projections, the accuracy, reliability, or reasonableness of the assumptions on which the Estimates and Projections are based, or the process of formulating any Estimates and Projections, including that any Estimates and Projections contained in this Announcement will be achieved. Artrya takes no responsibility to make changes to these statements to reflect change of events or circumstances after the release.

**For more information:**

**Corporate Enquiries**

**John Konstantopoulos**

Co-Founder and Chief Executive Officer

Tel: +61 8 6478 7816

Email: [contact@artrya.com](mailto:contact@artrya.com)

**Investor & Media Enquiries**

**David Allen or John Granger**

Hawkesbury Partners

Tel: +61 499 100 038 or +61 410 577 155

Email: [investors@artrya.com](mailto:investors@artrya.com)

For personal use only

**ARTRYA<sup>®</sup>**

(ASX: AYA)

## Company Presentation

Advancing U.S. Commercialisation

09 March 2026



Reshaping  
the Future of  
Heart Care

# Important Notice

## IMPORTANT NOTICE AND DISCLAIMER

These presentation materials have been prepared by Artrya Limited (**Artrya** or **Company**). By receiving the Presentation Materials, you acknowledge and represent to the Company that you have read, understood and accepted the terms of this disclaimer. You must read this important notice before you attempt to access the Presentation Materials. The information on this page is not part of the Presentation Materials. If you do not understand it, you should consult your professional adviser without delay.

## NOT AN OFFER

These Presentation Materials are for information purposes only. The Presentation Materials do not comprise a prospectus, product disclosure statement or other offering document under Australian law (and will not be lodged with the Australian Securities and Investments Commission) or any other law.

The Presentation Materials also do not constitute or form part of any invitation, offer for sale or subscription or any solicitation for any offer to buy or subscribe for any securities nor shall they or any part of them form the basis of or be relied upon in connection therewith or act as any inducement to enter into any contract or commitment with respect to securities. In particular, these Presentation Materials do not constitute an offer to sell or a solicitation to buy, securities in the United States of America. In particular, these Presentation Materials may not be released to U.S. wire services or distributed publicly in the United States.

These Presentation Materials have been prepared for publication in Australia and may not be released to US wire services or distributed in the United States. These Presentation Materials do not constitute an offer to sell, or a solicitation of an offer to buy, securities in the United States or any other jurisdiction. Any securities described in these Presentation Materials have not been, and will not be, registered under the U.S. Securities Act of 1933 and may not be offered or sold in the United States except in transactions exempt from, or not subject to, the registration requirements of the US Securities Act and applicable U.S. state securities laws.

The distribution of these Presentation Materials in other jurisdictions outside Australia may also be restricted by law and any such restrictions should be observed. Any failure to comply with such restrictions may constitute a violation of applicable securities laws. By accepting this document, you represent and warrant that you are entitled to receive such presentation in accordance with the above restrictions and agree to be bound by the limitations contained therein. For further information, see the section titled "International Offer Restrictions".

## NOT INVESTMENT ADVICE

The Presentation Materials are not investment or financial product advice (nor tax, accounting or legal advice) and are not intended to be used for the basis of making an investment decision. Recipients should obtain their own advice before making any investment decision.

## SUMMARY INFORMATION

The Presentation Materials do not purport to be all inclusive or to contain all information about the Company or any of the assets, current or future, of the Company.

BY THE BOARD OF ARTRYA LIMITED THIS PRESENTATION HAS BEEN APPROVED FOR RELEASE

The Presentation Materials contain summary information about the Company and its activities which is current as at the date of the Presentation Materials. The information in the Presentation Materials is of a general nature and does not purport to contain all the information which a prospective investor may require in evaluating a possible investment in the Company or that would be required in a prospectus or product disclosure statement or other offering document prepared in accordance with the requirements of Australian law or the laws of any other jurisdiction, including the United States of America.

The Company does not undertake to provide any additional or updated information whether as a result of new information, future events or results or otherwise.

## FORWARD LOOKING STATEMENTS

Certain statements contained in the Presentation Materials, including information as to the future financial or operating performance of the Company and its business operations, are forward looking statements. Such forward looking statements:

- are necessarily based upon a number of estimates and assumptions that, while considered reasonable by the Company, are inherently subject to significant technical, business, economic, competitive, political and social uncertainties and contingencies;
- involve known and unknown risks and uncertainties that could cause actual events or results to differ materially from estimated or anticipated events or results reflected in such forward-looking statements; and may include, among other things, statements regarding estimates and assumptions in respect of prices, costs, results and capital expenditure, and are or may be based on assumptions and estimates related to future technical, economic, market, political, social and other conditions.

The Company disclaims any intent or obligation to publicly update any forward-looking statements, whether as a result of new information, future events or results or otherwise.

The words "believe", "expect", "anticipate", "indicate", "contemplate", "target", "plan", "intends", "continue", "budget", "estimate", "may", "will", "schedule" and similar expressions identify forward looking statements.

All forward looking statements contained in the Presentation Materials are qualified by the foregoing cautionary statements. Recipients are cautioned that forward looking statements are not guarantees of future performance and accordingly recipients are cautioned not to put undue reliance on forward looking statements due to the inherent uncertainty therein.

## NO LIABILITY

The Company has prepared the Presentation Materials based on information available to it at the time of preparation. No representation or warranty, express or implied, is made as to the fairness, accuracy or completeness of the information, opinions and conclusions contained in the Presentation Materials. To the maximum extent permitted by law, the Company, its related bodies corporate (as that term is defined in the *Corporations Act 2001* (Cth) (**Corporations Act**)) and the officers, directors, employees, advisers and agents of those entities do not accept any responsibility or liability including, without limitation, any liability arising from fault or negligence on the part of any person, for any loss arising from the use of the Presentation Materials or its contents or otherwise arising in connection with it.

# Artrya at a glance – an attractive market and model

Salix® is the only real-time, point of care platform globally improving patient care and streamlining workflow

## Attractive Market

**\$4.4Bn<sup>1</sup>**

Market Size

**> 6%**

YoY Growth

## Commercial Momentum

- Salix® Platform & Plaque FDA cleared
- Three U.S. commercial customers and growing pipeline
- U.S. Customer Success team in place
- SAPPHIRE Study with major centres
- Strong balance sheet - \$76.5m cash<sup>3</sup>
- A\$535m market cap (ASX: AYA)<sup>2</sup>

## Differentiated Product

- Single, unified CCTA Reporting Platform within 10 mins
- Real-time report, Plaque, and FFRCT<sup>4</sup> analysis
- Streamlines clinical workflow and improves patient care

## Leading Institutional Investors:

REGAL  
FUNDS MANAGEMENT

Wilson  
Asset Management

PARADICE  
INVESTMENT MANAGEMENT

1. Company Presentation – slide 7 – Released to ASX on 1 September 2025  
2. As of 06 March 2026  
3. Pro forma cash including cash and term deposits As at 31 December 2025  
4. Salix® Coronary Flow not yet cleared by FDA

# Recent Achievements

FY2026 marks commercial scale-up following the platform laid in 2025

FY2026 Execution & Growth	
 <b>FDA activity</b>	<b>FDA clearance</b> for Salix® Coronary Plaque <b>Successful FDA Q-Sub meeting</b> for Salix® Coronary Flow <b>Anticipated FDA clearance</b> of Salix® Coronary Flow by 30 June 2026
 <b>Commercial progress</b>	<b>Three U.S. commercial customers launched</b> - Tanner Health, Cone Health, and Northeast Georgia <b>Further commercial pipeline</b> through SAPPHIRE participants
 <b>U.S. Go to market</b>	<b>General Manager U.S.</b> hired <b>U.S. Customer Success team</b> established Additional <b>U.S. Non-Executive Director appointed</b>
 <b>SAPPHIRE Study</b>	<b>Secured Study participants</b> - Mass General Brigham, Piedmont Health, Huntsville Hospital, Dignity Health, HCA Midwest
 <b>Capital management</b>	<b>\$80M raised</b> to fund U.S. expansion strategy

# Coronary artery disease is a large and growing health challenge

Cardiovascular Disease Costs will exceed US\$1 trillion by 2035 – American Heart Association<sup>4</sup>


## US\$4.4 billion\*

### Serviceable Addressable Market (US)

U.S. patients undergoing CCTA + Plaque Assessment

### Tailwinds impacting TAM growth

- **Guideline Support** – AHA/ACC recommend CCTA as a first-line diagnostic for patients with chest pain<sup>5</sup>.
- **Attractive reimbursement** – **Category I CPT codes** support CCTA, plaque assessment, and FFRCT<sup>3</sup>.
- **CT-First Adoption** – Strong shift from invasive angiography and SPECT toward **non-invasive CT-based pathways**.



## 6.2% YOY

Projected growth in Cardiac CCTA scans to 2028<sup>1</sup>

### \* Assumptions

- National Average Medicare Rate
  - Reimbursement for Automated Plaque – US\$950 (CPT 0625T<sup>3</sup>)
  - Reimbursement for FFRCT – US\$887 (CPT 75580<sup>3</sup>)
- TAM estimated as total of all scans receiving Plaque reimbursement only
- FFRCT procedures have not been included in TAM

1 <https://www.dicardiology.com/article/rising-demand-cardiac-ct-positions-market-major-growth>  
2 Frost & Sullivan Analysis – Artrya Prospectus – <https://wcsecure.weblink.com.au/pdf/AYA/02456983.pdf>  
3 <https://cardiovascularbusiness.com/topics/cardiac-imaging/cms-increases-medicare-payments-cardiac-ct-ccta>  
4 Cardiovascular Disease: A Costly Burden for America – Projections Through 2035. American Heart Association.  
5 American College of Cardiology – 2021 AHA/ACC Chest Pain Guideline Perspectives

# Current methods for diagnosing coronary artery disease are outdated

A point of care solution for rapidly diagnosing high-risk plaque is a holy grail for clinicians



## Ineffective

Old methods ineffective in **detecting high-risk plaque**<sup>1</sup>




## Avoidable

**55% of invasive procedures** are unnecessary<sup>2,3,4</sup>




## Slow & Costly

Outdated methods are time consuming and higher cost to deliver



## Pressure on Hospitals

CCTA **demand is outpacing** clinical capacity  
Hospitals **need higher throughput**  
Current solutions **delay care / increase backlogs**




1. Comprehensive plaque assessment by coronary CT angiography. Nat Rev Cardiol 11, 390–402 (2014)
2. Low Diagnostic Yield of Elective Coronary Angiography. New England Journal of Medicine. March 11, 2010.
3. Temporal Trends in the Frequency of Inducible Myocardial Ischemia During Cardiac Stress Testing. Journal of the American College of Cardiology (JACC). March 12, 2013.
4. Trends in U.S. Cardiovascular Care: 2016 Report from 4 ACC National Cardiovascular Data Registries. JACC. March 2017

# Salix<sup>®</sup> provides streamlined, real-time patient assessment

Clear clinical insights into actionable decisions in minutes

For personal use only



## Point of care real-time analysis – no human in the loop

CCTA analysis in under 10 mins increases capacity and throughput

## Real-time Plaque and Flow Analysis

Automated assessment of plaque and FFRCT for improved treatment

## Unified Reporting Platform

Consolidates CCTA reporting on platform, reduces physician fatigue and reporting costs by consolidating tools



## Streamlined Workflow and Enhanced profitability

Improved efficiency, transforms CCTA into a scalable, high-margin service line

\* Salix Coronary Flow not yet cleared by FDA

# From off-site workflows to 10-minute decision

Salix<sup>®</sup> fits directly into the existing clinical workflow; no uploads, no portals, no off-site vendors



For personal use only



Salix<sup>®</sup> demonstration



# Go to Market strategy

---

Commercial pathway for 2026 and beyond



# Salix<sup>®</sup> is a single platform solution built to scale

Modular software powering complete, scalable CCTA analysis for coronary artery disease

Increasing clinical utility & revenue opportunity

**US\$887**  
CPT1 Per scan<sup>1</sup>

+

**US\$950**  
CPT1 Per scan<sup>1</sup>

+

**US\$325**  
CPT1 Per scan<sup>1</sup>

## Salix<sup>®</sup> Coronary Flow Module

Non-invasive blood flow assessment.

**Final validation stage – FDA clearance expected e/o FY26**  
Avoids unnecessary invasive angiograms.

## Salix<sup>®</sup> Coronary Plaque Module

Detailed plaque characterisation, dispersion, & stenosis analysis.

**FDA cleared – automatically enabled on SCA**  
Quantifies and characterises plaque within the coronary arteries.


## Salix<sup>®</sup> Coronary Anatomy Platform

Core platform enabling plaque visualisation, workflow optimisation, physician productivity, and CCTA reporting.

**FDA cleared – launched commercially in the U.S.**  
Core Platform for real-time, whole-heart characterisation.

# From strategy to scale: executing with precision

Delivering focused execution through three clear go-to-market strategies



For personal use only

# Salix® platform successfully launched in three U.S. systems

All three U.S. integration partners have been converted to commercial customers



## Live from July 2025

- ▶ 5-year Commercial Agreement
- ▶ Minimum US\$0.6m \*
- ▶ 5 Hospitals, cardiovascular centres and 30 practices

*"...we believe Artrya's Salix® platform with its AI-powered, user friendly and near real-time outcomes, provides our clinicians with another key tool to help detect heart disease earlier and save lives."*

- Loy Howard, President and CEO of Tanner Health



## Contract signed December 2025

- ▶ 3-year Commercial Agreement
- ▶ Minimum US\$0.3m \*
- ▶ 5 Hospitals, outpatient centres, and physician practices

*"This latest A.I.-enabled technology reflects our commitment to advancing cardiovascular medicine and ensures patients across Georgia Heart Institute can benefit from faster, more accurate diagnoses and improved outcomes."*

- Zaid Said, MD, FACC, Medical Director of Cardiac CT and MRI for Georgia Heart Institute



## Contract signed December 2025

- ▶ 5-year Commercial Agreement
- ▶ Minimum US\$0.45m \*
- ▶ 5 hospitals, ambulatory care centres, outpatient surgery centres, urgent care centres, >120 physician practices


*We are delighted to build on our successful collaboration with Artrya and bring this transformative Salix® technology into the clinical workflow across our network. Through this process we can see major benefits in the way that Salix® can provide accurate, point-of-care interpretation of CCTA scans within minutes.*

- Dr. Wesley O'Neal, MD, Medical Director of Cardiac CT and Nuclear Cardiology at Cone Health

\* Minimum contract values relate solely to the monthly subscription of Salix® Coronary Anatomy, with additional fee-per-scan revenues from the Salix® Plaque and Flow (once approved) modules

# Building a U.S. footprint to support leading health systems

Foundation customers, SAPPHIRE sites, and our Atlanta support pod working together to drive U.S. growth



SAPPHIRE Study partners

Commercial partners

# Expanding clinical utility with Salix<sup>®</sup> Coronary Flow module

Expands use and utility of Salix<sup>®</sup> platform with access to U.S. reimbursement once FDA cleared

01

## Robust FDA submission developed

Q-Sub meeting confirms approach and requirements

02


## Final module calibration completed early 2026

Sourced high-quality imaging for additional module analysis – sensitivity and specificity meet and exceed FDA targets

03

## Planned FDA clearance by end of FY2026

Timing is estimated and subject to FDA process



\* Salix Coronary Flow not yet cleared by FDA

# Flagship Novel Plaque Study - SAPPHIRE

The SAPPHIRE Study will validate the novel Salix® Plaque Dispersion Score to identify patients at risk of heart attack

## Overview

- Evaluate Salix® PDS assessing cardiovascular risk
- Specific focus on CAD in women.
- 6 high volume U.S. Centres
- Multicentre, retrospective study
- **HCA, Dignity Health, Mass General, Ascension, Piedmont Healthcare, and Huntsville** as participants

## Key Phases

**Phase 1:** Identify patients at risk using Salix® Plaque analysis compared to current standard of care. ~ 12 months

**Phase 2:** Leverage Salix® Plaque Dispersion Score to further risk stratify patients and change treatment. ~ 12 months

## Key Benefits

01

Predict future adverse events and improve treatment

02

Build clinical awareness and credibility in US

03

Accelerate commercial adoption in US hospitals

# Summary and Outlook for 2026: Scaling Salix® in the U.S.

Building the foundation for sustainable commercial growth through revenue, clinical validation, and operational readiness.



## Drive Commercial Growth

- 1 Generating annual revenue** from SCA, SCP and SCF from U.S. operations (SAPPHIRE conversions & foundation customers).
- 2 3 foundation customers live** and operational



## Clinical & Operational Excellence

- 3 6 hospital systems active** in the SAPPHIRE Study; Initial Phase 1 data analysed.
- 4 SCF cleared through FDA.**
- 5 CX & Support framework implemented**



## Build for Scale & Credibility

- 6 Full U.S. organisation & governance operational** (core recruits, executives, Board/CAB).
- 7 Clinical credibility** through papers published and conferences presented.

Note: 2026 Calendar Year

# Building a Sustainable Competitive Advantage

Competitive advantage built on product strength, pricing flexibility, and customer experience

## Our strategy is built on three reinforcing pillars:

### ▶ **Product Experience:** Real-time, platform infrastructure

We deliver the strongest product in market, combining real-time diagnosis with integrated workflows and a user experience designed for effortless adoption.

### ▶ **Price:** Adoption-aligned economics

Our pricing is competitive and differentiated through a revenue share model that reduces customer risk and directly aligns with our mutual success.

### ▶ **Customer Experience:** Growth & retention engine

We provide an easy experience at every stage of the journey; from onboarding to support to reducing friction and making every interaction simple and reliable.



Superior product. Differentiated value. Exceptional customer experience.  
**Saving Lives**

[www.artrya.com](http://www.artrya.com)

### Corporate Enquiries

**John Konstantopoulos**  
Co-Founder and Chief Executive Officer  
Tel: +61 8 6478 7816  
Email: [contact@artrya.com](mailto:contact@artrya.com)

### Investor & Media Enquiries

**David Allen or John Granger**  
Hawkesbury Partners  
Tel: +61 499 100 038 or +61 410 577 155  
Email: [investors@artrya.com](mailto:investors@artrya.com)

